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IDENTIFYING THE ROLE OF MUSCLE TRAUMA ON 
HETEROTROPHIC OSSIFICATION 
PAUL GILBERT MURPHY JR. 
ABSTRACT 
Introduction:  
Musculoskeletal trauma can lead to the abnormal accumulation of ectopic bone tissue, a 
process otherwise known as heterotrophic ossification. Many stem cell populations have 
been implicated in the osteogenic response initiated by injured musculoskeletal tissue. 
Pax7 expressing muscle stem cells, called satellite cells, have been identified as the major 
contributor to skeletal muscle repair. Additionally, cells positive for Pax7 are involved in 
the formation of ectopic bone that is induced by DBM implantation in the presence of 
trauma.  In an attempt to better understand the mechanism of ectopic bone formation 
following injury, the presence of myogenic, osteogenic, chondrogenic, and adipogenic 
gene markers were explored within and in proximity to the implanted DBM.  
Objectives:  
To establish the contribution of post-natal muscle stem cells and associated relevant 
molecular mechanisms involved in the DBM induced ectopic bone formation following 
muscle trauma.  
Methods:   
Tamoxifen inducible Pax7tm1(cre/ER2)Gaka/J mice were crossed with B6.Cg-
Gt(ROSA)26sor<tm14(CAG-tdTomato)Hze>/J. Animals were back crossed with 
	
	 vi 
B6,129S7-Rag1tm1Mom/J mice, creating a Pax7/Ai14/Rag reporter enabling ectopic bone 
to be induced with human DBM.  Mice were dosed with two injections of tamoxifen, 48 
hours apart, then allowed a 30-day washout period. Animals received an implant of 50 
mg of human DBM supplemented with 0.1 µg of bone morphogenetic protein 2 (BMP-2) 
and were placed on the femoral periosteum or intramuscularly on the upper hind limb, in 
order to induce ectopic bone formation. Muscle trauma was introduced to each limb after 
DBM surgery by a blunt impact trauma. The DBM implant, surrounding muscle and the 
femur were harvested either two, eight, or sixteen days following surgery.  Tissue 
samples were radiographed, after which either mRNA or histological analysis was carried 
out.  Gene expression was analyzed by real time qPCR using mRNA extracted from 
implant or muscle surrounding the implant.  Tissue samples destined for histology were 
frozen, sectioned and then fixed on slides for processing.  Fast Green/Safranin-O staining 
allowed for visualization of the cartilage and bone tissue at the site of the ectopic bone. 
Immunofluorescence was used to observe the presence of Pax7 positive, osteogenic and 
chondrogenic cells adjacent to or interacting with the DBM implant.   
Results:  
Pax7 and Prx1 expressions within periosteal and intramuscular implants did not differ 
significantly in terms of time post-surgery or implant location. Certain chondrogenic 
(ColX) and osteogenic (Sp7 and DMP1) followed previously established patterns in 
expression following periosteal implantation surgery. Finally, the expression of Pax7 and 




The combination of DBM implantation surgery and muscle contusion yields a large and 
varied genetic and physiological response.  Many of the genes involved in the formation 
of ectopic bone following muscle injury were characterized.  The data reaffirms 
previously studied patterns of expression following periosteal DBM administration, and 
suggests that this pattern is delayed for those implants located within the muscle.  
viii 
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Orthopaedic injury refers to the disruption of the musculoskeletal complex 
consisting of bone and associated soft tissues, including tendons, muscles, and ligaments. 
One of the most common being bone fractures.  In the United States alone, approximately 
7.9 million fractures occur per year (American Academy of Orthopaedic Surgeons 2000).  
Fracture treatment is initiated with three main goals, effective stabilization, limb 
preservation and reduction of high-level risks such as a fat embolism or organ puncture 
(Balogh et al. 2012).  However, different regenerative cell populations will be recruited 
depending on the severity of the bone fracture as well as the trauma to the surrounding 
soft tissues (Einhorn and Gerstenfeld 2015).  Another consideration is the severity of 
injury to the muscles near the fracture site that can affect limb viability and quality of 
life.  It has been previously suggested that skeletal muscle aids with the fracture repair 
(Hamrick, 2011).  Thus, it is our focus to attempt to elucidate the cell populations and 
biological mechanisms related to the interconnection of bone repair and muscle 
regeneration following injury.  
	
Musculoskeletal Trauma 
Injury to the musculoskeletal system results in the recruitment of a wide variety of 
cells, and the expression of proteins, and cytokines.  It is well established that fracture 
repair will closely recapitulate the endochondral ossification process seen throughout 
embryonic bone development (Ferguson et al. 1999).  While many fractures will repair 
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successfully, approximately 10% of fractures will result in impaired healing seen with 
delayed or nonunion fractures, and will require intervention including surgery or non-
invasive biogenic treatments (Einhorn & Gerstenfeld, 2015).   
Stem cells and regenerative factors that contribute to injury repair arise from the 
locally affected tissues, including muscle, bone, and the vasculature (Bragdon & Bahney 
2018).  Crosstalk between the cellular compartments of the muscle and bone occurs 
through the periosteum, the layer of tissue which encompasses the outer surface of bone 
(Lai et al. 2014).  Fractures can increase the communication between these tissues by 
introducing new areas of contact between the muscle and impinging bone. Muscle tissue 
plays an important function in ensuring proper regeneration of bone. It has been shown 
that removal of muscle stem cells, known as satellite cells, will significantly impair the 
bone repair process (Abou-Khalil et al. 2014). However, the degree of muscle trauma will 
affect the tissues ability to aid in bone recovery, as massive muscle trauma surrounding a 
fracture will delay bone regeneration (Claes et al. 2017).  
	
Endochondral Ossification 
 Embryonic bone development occurs through two distinct processes.  The 
majority of the craniofacial bones are formed through intramembranous ossification, the 
first of these processes (Vortkamp et al. 1998).  This involves mesenchymal stem cells 
condensations resulting in the direct formation of osteoblasts (Kronenberg 2003).  The 
remaining portions of the axial skeleton as well as the entire appendicular skeleton are 
formed through the process of endochondral ossification.  Instead of a direct 
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differentiation to osteoblastic cells, mesenchymal stem cells will first differentiate into 
chondrocytes forming a cartilage template, which is gradually replaced by bone tissue 
(Erlebacher et al. 1995).  
 This process begins with the migration of the mesoderm-derived cells to regions 
of future bone and begin to express sonic hedgehog (Shh) (Ehlen et al., 2006).  Shh 
encodes a protein in the early limb bud, which will help establish a pattern of growth 
posterior to anterior, i.e. thumb to pinky finger (Lieberman & Friedlaender, 2005).  A 
target of Shh is the expression of the transcription factor, Sox9, which is vital for the 
differentiation of mesenchymal progenitor cells into chondrocytes (Ehlen et al., 2006), 
(Akiyama et al. 2002). Differentiated chondrocytes secrete a cartilage matrix composed 
of Type II collagen and proliferate in a parallel, unidirectional pattern (de Crombrugghe 
et al., 2001). This chondrocyte growth is responsible for the template that will eventually 
become bone, as seen in Figure 1. Chondrocyte proliferation and inhibition of 
hypertrophy is maintained through Indian hedgehog (Ihh) signaling (Olsen et al., 2000) 
Both Shh and Ihh, have been implicated in the regulation of fibroblast growth factors 
(FGFs) and bone morphogenetic proteins (BMPs), which are instrumental in 
musculoskeletal development (Kronenberg, 2003).  Members of the FGF gene family are 
expressed throughout endochondral ossification and contribute to the regulation of 
chondrocyte proliferation and differentiation (Ornitz & Marie, 2002).  Additionally, BMP 
activity is observed throughout the bone forming process. Early effects of these factors 
include modulating the differentiation of mesenchymal cells to chondrocytes as well as 
that of osteoprogenitor cells to osteoblasts (Moucha & Einhorn, 2005).  
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As the proliferation of chondrocytes progress, chondrocytes begin to exit the cell 
cycle and undergo hypertrophy (de Crombrugghe et al., 2001). Hypertrophic 
chondrocytes have multiple effects during bone development. First, hypertrophic 
chondrocytes secrete Collagen X and mineralize the surrounding matrix, marking a 
transition to mineralized bone (Provot & Schipani, 2005). Secondly, these cells express 
high levels of vascular epithelial growth factor A (VEGF-A) that induces blood vessel 
invasion (Gerber et al, 1999). Lastly, hypertrophic chondrocytes near the outer boundary 
of the cartilage template will signal perichondrial cells to differentiate into osteoblasts, 
which in turn forms the bone collar, seen in Figure 1 (Kronenberg, 2003). 
 Hypertrophic chondrocytes eventually undergo apoptosis, and this area is invaded 
by osteoclasts and osteoblasts. These cells will resorb the cartilage matrix and form 
trabecular bone (Provot & Schipani, 2005). The area of mineralized bone will eventually 
grow to become the primary ossification center with two longitudinally migrating fronts 
of hypertrophic and apoptotic chondrocytes, shown in Figure 1. At this point, 
chondrocytes in peripheral locations cease to proliferate and become hypertrophic, 
inducing the creation of secondary ossification site with processes similar to that seen in 
the primary site (Mackie et al. 2008).  
 The site between the primary and secondary ossification centers, known as the 
growth plates are seen in Figure 1, is responsible for the post-natal longitudinal growth of 
the bones (Hunziker, 1994).  Growth plates contain cells undergoing the same processes 





Figure 1: General Schematic Overview of Endochondral Ossification. Computer 
generated rendering of the step-wise formation of bone through endochondral 
ossification. (Modified from Mackie et al., 2008). 
 
 
Ectopic Bone  
 Heterotopic ossification (HO) is the abnormal accumulation of bone in the bodies 
of soft tissue.  Clinically, HO manifests in the two forms, the rarer hereditary conditions 
and more common acquired forms.  Two rare genetic disorders, fibrodysplasia ossificans 
progressive and progressive ossific heteroplasia, are characterized by a gradual 
debilitation through aberrant bone growth (Sankar et al., 2015). Acquired ectopic bone is 
much more common and is the result of trauma to the musculoskeletal system or a 
neurogenic insult, such as damage to the spinal cord or central nervous system (Garland 
1991).  While the molecular explanation for why HO occurs remains ambiguous, it has 
been established that muscle trauma is a common link between many types of HO (Li et 
al., 2019).   
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HO is a common complication seen following hip replacement surgeries as well 
as in incidents of high energy trauma.  20% of patients receiving total hip arthroplasty 
develop HO (Anthonissen et al., 2016). The clinical relevance of these hip ossifications 
can be determined by characterizing bone growth in terms of the Brooker classification 
system (Brooker et al. 1973). Prophylaxis of HO is the most common intervention 
strategy for patients assumed to be high risk for ectopic bone development.  These 
include patients with a history of HO or those with concomitant severe traumatic brain 
injury (Balboni et al., 2006; Huang et al. 2017).  The prophylactic interventions most 
often used include non-steroidal anti-inflammatory drug (NSAID) administration and 
radiotherapy (Baird & Kang, 2009).  Although the successful preventative measures have 
been illuminated, no gold standard exists for therapeutic treatment of HO once the 
abnormal bone has development.  
Moreover, ectopic bone can be induced in various locations by the implantation of 
mesenchymal stem cells subcutaneously or intramuscularly (Scott et al., 2012).  Ectopic 
bone can also be induced by other osteo-inductive factors such as demineralized bone 
matrix (DBM) or bone morphogenetic protein 2.  Demineralized bone matrix is an 
allograft that is clinically used to induce bone formation at desired sties. The formation of 
ectopic bone following DBM administration is well-established in literature (Urist, 1965).  
Further, Urist found that the BMPs were the crucial factors necessary for ectopic bone 
formation (Urist et al., 1979).  While these proteins and other osteo-inductive factors 
often only make up 5% of DBM samples, addition of supplemental BMPs can increase 
the extent of the ossification process (Lee et al., 2005).  Other members of the BMP 
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family, such as BMP-7, have also been implicated as osteo-inductive factor that are 
considered essential in the formation of ectopic bone following muscle injury (Li et al., 
2019). 
In combination with one another, DBM and BMP-2 have a potent ability to 
induce de novo bone tissue. Interestingly, previous research found that the amount of 
BMP-2 required to induce ectopic bone formation is significantly decreased in cases of 
muscle trauma when compared to non-injured controls (Moore, 2019).		
 
Skeletal Stem Cells 
 Stem cells are unspecialized cells with the unique capability to both regenerate 
themselves, as well as differentiate into a more specialized cell type.  Stem cells can be 
characterized by their ability to differentiate.  A totipotent stem cell is capable of 
generating all of the tissues of an organism, while a pluripotent stem cell is able to 
differentiate into any cell type of the three embryonic germ layers.  Multipotent stem 
cells can give rise to more than one cell type, such as the hematopoietic stem cell.  And 
the unipotent stem cell that can only differentiate into one cell type. For the purposes of 
this paper, the latter two stem cells are relevant, since they can be found in their relative 
tissues throughout the adult body.  These cells persist throughout an individual’s lifetime 
to provide for cellular turnover and in cases of injury.  
 Mesenchymal stem cells (MSCs) are a multipotent stem cell that have the 
capability of differentiating into many different components of the musculoskeletal 
system in vitro including bone, cartilage, and fat cells (Fernández-Vallone et al., 2013).  
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While there is some debate about the precise definition of this term, MSCs associated 
with the bone marrow are often referred to as skeletal stem cells.  Mature cells derived 
from skeletal stem cell lineages have the unique ability to transdifferentiate.  It has been 
shown that chondrocytes differentiate into osteoblasts during endochondral ossification, 
both during development and fracture repair in mice (Zhou et al., 2014).  Additionally, 
bone is the only tissue capable of complete regeneration following injury (Marsell & 
Einhorn, 2011). This restoration of pre-injury structure and function could potentially be 
due to the plasticity of skeletal stem cells.  
 Skeletal stem cells are paramount in the effectiveness of innate musculoskeletal 
injury repair.  Stem cells used in regeneration of damaged tissue are recruited from the 
bone marrow, periosteum and accompanying soft tissues.  It has been suggested that the 
majority of stem cells involved in fracture repair originate from the periosteum (Colnot,  
2009).  Other studies have shown that myogenic progenitor cells can contribute to the 
formation of a fracture callus by differentiating into osteogenic lineages. Yet, the extent 
of muscle progenitor cell activity on bone healing depends on whether the fracture open 
or closed in terms of exposure of the marrow to the surrounding soft tissue (Liu et al., 
2011).  The influence from each of these stem cell populations is additionally dependent 
on the severity of tissue damage as well as the local strain placed on the injury caused by 
intervention (Balboni et al., 2006).  
Prx1 is a stem cell marker relevant to embryonic bone development as well as 
post-natal skeletal regeneration.  Its sequence is defined as a homeobox-gene and is 
expressed by limb bud mesenchymal cells during embryonic bone development (Martin 
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& Olson, 2000).  The Prx1 expressing cells are considered predecessors to osteogenic and 
chondrogenic lineages, since expression precedes that of Sox9 during development 
(Akiyama et al. 2005).  Prx1 expressing cells are located at the periosteal surface and 
within the marrow cavity of adult tissues, suggesting that they are a potential progenitor 
cell population which persists throughout adulthood (Kawanami et al. 2009).  Cells 
expressing the gene aid the formation of the soft callus post fracture, due to their presence 
in the periosteal surface as well as their relationship to Sox9 during development (Murao 
et al., 2013).  
 
Satellite Cells and Pax7  
 Skeletal muscle is one of three types of muscle found in the body. It is a striated 
tissue consisting of parallel bundles of multinucleated fibers, many of which are 
connected to bone via tendons. These fibers are under control of the somatic nervous 
system (under voluntary control) and have the contractile ability, allowing for movement 
of gross and fine body movements. The satellite cell is considered the adult myogenic 
stem cell, responsible for repair, maintenance, and renewal of muscle (Seale & Rudnicki, 
2000). These cells reside under the basement membrane of each myofiber, hence their 
namesake (Zammit et al., 2006). Satellite cells are most characteristically recognized 
through their expression of the transcription factor, Pax7 (Seale et al., 2000). In adults, 
the majority of Pax7 expressing cells remain quiescent in their niche, adjacent to the 
sarcolemma (Schultz et al., 2006). These cells can be recruited following muscle injury 
caused by an external stimulus (Dumont et al., 2015). Following trauma to muscle tissue, 
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satellite cells begin differentiation into myogenic precursor cells as well as replenish its 
population through asymmetrical divisions, as seen in Figure 2 (Sacco et al., 2008). Pax7 
is expressed in both arrested and actively dividing satellite cells, and is downregulated by 
the differentiation into skeletal muscle cell precursors (Sambasivan & Tajbakhsh, 2007). 
Activated satellite cells are of particular interest due to their ability to move throughout 
tissue. Cells can migrate between myofibers and even between fascicles, traversing 
barriers such as the basal lamina (Watt et al., 1987). Additionally, Pax7 cells are of 
clinical importance since they are essential for muscle regeneration following trauma. In 
a study conducted with Pax7-/- mice, a failure to regenerate skeletal muscle following 
muscle tissue depletion was observed (Sambasivan et al., 2011). Muscle mass instead 







Figure 2. Activation of Satellite Cells. Artistic depiction of satellite cell activation and 
division process which occurs following muscle trauma. Relevant cell populations are 
drawn in relation to the muscle fiber. The schematic follows the division process while 
illustrating important expressed genes throughout. (Modified from Tedesco et al., 2010) 
	
As depicted in Figure 2, satellite cell differentiation and proliferation does not 
rely solely on Pax7 expression, but is also regulated by myogenic factor 5 (Myf5) and 
myoblast determination protein 1 (MyoD) expression. Most quiescent satellite cells in the 
basement membrane will express both Pax7 and Myf5. However, a small population of 
these Pax7 positive cells have never expressed the Myf5 gene (Tedesco et al. 2010).  This 
small number of Pax7 cells are responsible for an asymmetrical division, which results in 
a Pax7+Myf5– satellite cell, identical to the parent cell, and one Pax7+Myf5+ satellite 
daughter cell, potentially destined for differentiation (Kuang et al., 2007).  Twenty four 
hours following trauma, 98% of the activated satellite cells, expressing both Pax7 and 
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Myf5, will begin expressing MyoD (Zammit et al., 2002).  The cells now expressing 
MyoD will downregulate Pax7 and progress to myogenic differentiation (Zammit et al., 
2004). A small portion of these activated cells will not express MyoD and will be 
removed from the differentiation process. These Pax7+Myf5+/MyoD- will remain in 
clusters, some of which return to their quiescent state while others remain in this semi-
activated state, prepared for proliferation if needed (Tedesco et al., 2010).  
 Finally, satellite cells are also capable of differentiating into other mesenchymal 
lineages, including osteogenic, chondrogenic, and adipogenic progenies in vitro (Asakura 
et al., 2001).  Recent studies have shown that without muscle injury, Pax7+ cells are not 
found to contribute to fracture repair or DBM-induced ectopic bone formation (Molinelli, 
2018).  However, when the muscle is injured following DBM implantation, Pax7+ 
satellite cells are recruited to aid in heterotrophic ossification (Moore, 2019).  Therefore, 
the focus of this research is to further illuminate other mesenchymal genes involved in 








1) Determine the molecular effect muscle trauma has on HO formation. The gene 
expression profiles for bone, cartilage, fat, and muscle were probed across time 
using qPCR. The ectopic bone tissue was induced either at the periosteal surface 
or within a muscle pouch. Histological and immunofluorescence were used to 
confirm the presence of different cell populations.  
 
2) Identify the cross talk between muscle and HO formation following muscle 
trauma.  The gene expression profiles for muscle regeneration and BMP signaling 

























Thermo Fischer Scientific (Waltham, MA) provided the materials and equipment 
utilized throughout the project, unless specifically stated otherwise.  
 
Animals 
Mouse studies were approved by the Institutional Animal Care and Use Committee at 
Boston University. Animals were housed under standard conditions in the Boston 
University animal facility. The mouse strain, Pax7/Ai14/Rag was used for this study and 
were bred at Boston University. Crosses of mice to create this strain was previously 
described (Moore, 2019). Both male and female mice were used throughout the study.  
 
Tamoxifen Injections 
Tamoxifen solutions used for injections were prepared by adding 400 mg of 
tamoxifen to 40 mL of corn oil.  Tamoxifen was completely dissolved in solution by 
repetitive sonication in an ice-cold ethanol bath for 15 minutes intervals. After solvation, 
the corn oil: tamoxifen solution was sterile filtered with 10-ml syringe and an in-line 0.45 
µm sterile filter. The solution was then aliquoted into 2 ml tubes, and stored -80 °C. 
Two rounds of tamoxifen injections were delivered to each animal 
intraperitoneally with a dose of 10 µL/g of body weight. Each injection occurred 48 hours 
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apart. A month-long tamoxifen washout period elapsed before animal surgery was 
completed. 
 
Demineralized Bone Matrix Implantation Surgery 
Demineralized bone matrix, DBM, (Grafton Putty) was obtained from Medtronics 
Inc. (Minneapolis, MN) with a material transfer agreement. Using 4% isoflurane, the 
mice were anesthetized in a chamber before being moved to a heated pad. Anesthesia 
administration of 2% isoflurane was continued throughout the surgery via a nose cone. 
Animals were given subcutaneous injections of both an antibiotic and analgesic, 0.01 mL 
of 2.27% Baytril and 0.1 mL of Buprenex, respectively. Incision locations on both hind 
limbs were first shaved and prepped with the antiseptic Betadine. The DBM (50 mg)  
supplemented with 0.1 µg of BMP-2 was implanted according to (Kuang et al. 2007). 
Implant location differed for each hind limb. The right limb received an implant placed 
on mid-shaft periosteum, while the left limb received an implant into a muscular pouch. 
This implant was placed in a space made between the medial gluteal and quadriceps 
muscle. After implantation, a muscle contusion was created using a blunt mass dropped 
from 31 mm (Grode, Hardin, & Oberfeld, 2017).  
 
Harvest & X-ray Imaging 
Mice hind limbs were harvested at three different time points after implantation 
surgery and injury. These included post-operative days (POD) 2, 8, and 16. Mice were 
sacrificed using carbon dioxide euthanasia, which was subsequently followed by 
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secondary euthanasia caused by cervical dislocation. Animals were weighed and 
radiographs (Denville Scientific HyBlot CL film, Metuchen, NJ) were obtained of each 
hind limb using the Faxitron MX-20 Specimen Radiography System (Tucson, AZ) set at 
30 kV for 40 Seconds. Radiographs were subsequently developed using a Konica Minolta 
SRX-101A film processor (Wayne, NJ). X-rays were utilized to allow for the 
visualization of ectopic bone formation.  
Samples used for mRNA extractions, the femur, surrounding muscle, and implant 
were harvested separately and placed into individual Eppendorf tubes. These tissues were 
snap frozen in liquid nitrogen and stored at -80 °C until processing. For samples used in 
frozen histology, femurs and the surrounding soft tissue were collected together and fixed 
in 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO) for at least 72 hours at 4 °C. 
Care was taken to ensure the implant was not disrupted during the harvest.  
 
Decalcification 
Following fixation with PFA, tissue samples were washed with 1x phosphate-
buffered saline (PBS) three times for 10 minutes. The samples were then loaded into 
Sure-Tek 2 embedding cassettes and placed in a 1 L container filled with 14% 
Ethylenediaminetetraacetic Acid (EDTA) (Acros Organics, NJ) and a stir bar. The 
container used was covered with foil to ensure the samples was protected from light. 
Samples were placed on a stir plate in 4 °C for at least a week, allowing for constant 
agitation. After 7 days, a 27-gauge syringe was used to probe the resistance and hardness 




After decalcification of the samples was complete, they were removed from the 1 
L container and processed for standard frozen histology. The samples were moved from 
their cassettes and washed with various solutions. The samples were first placed in a 
7.5% sucrose/PBS solution for at least 24 hours. This was followed by a 24-hour 
incubation in 30% sucrose/PBS solution. Finally, these were placed in 50% (30% 
Sucrose)/50% Tissue Plus Optimum Cutting Temperature (OCT) compound for a final 24 
hours.  
Following immersion in varying sucrose solutions, samples were embedded with 
OCT in plastic molds. Samples were placed in the molds and gently covered with OCT, 
while ensuring no air bubbles formed. A metal container filled with 2-Methylbutane was 
placed in a large receptacle of liquid nitrogen and chilled. The plastic molds with the 
samples were then carefully lowered into the 2-Methylbutane for 30 seconds, allowing 
the tissue sample and OCT to freeze. Once completely frozen, the samples were removed 
from their plastic mold and stored at -80 °C.  
Finally, tissue samples were sectioned on a Reichert Jung Cryocut 1800 (Wetzlar, 
Germany). The width of each section was between 8 and 10 µm. Sections were air dried 
on slides and then stored at -80 °C for various staining procedures.   
 
Safranin-O & Fast Green Staining 
Sectioned samples were washed two times in 1X PBS for 3 minutes followed by 
dH20 for five minutes. Sections were then placed in a 0.05% fast green solution for one 
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minute. Tissue samples were then dipped five times 1% acetic acid.  Slides were then 
placed in 0.2% safranin-O solution for a final minute. After staining, the sections were 
allowed to air dry before cover-slipping with Permount.  
 
Immunofluorescence 
To prepare fluorescent samples for cover-slipping, sectioned samples were 
removed from -80 °C storage and washed with 1x PBS two times for 3-5 minutes.  After 
air drying, samples were encircled with a PAP PEN (SuperHT) hydrophobic marker to 
ensure appropriate delivery of antibody solution onto samples.  Antibodies were diluted 
using a buffer consisting of 1X PBS, 1% bovine serum albumin, and target antibody.  The 
primary antibody, ColX, was used at  1:1000.  After application of primary antibody 
dilutions, samples were incubated overnight at 4 °C.  The samples were then washed 3 
times with 1X PBS before secondary antibody administration.  A secondary antibody 
dilution, using the same materials as previously noted, was made using AlexaFour 488 
donkey anti-rabbit antibody at a concertation of 1:1000. This secondary antibody was 
applied to the samples and allowed to incubate for 1 hour at room temperature, protected 
from light. The samples were then again rinsed washed 3 times with 1X PBS, allowed to 
air dry, then were mounted using Molecular Probes Prolong Gold Antifade Reagent with 
DAPI.  Any air bubbles were delicately removed using the blunt end of a cotton swab. 
Primary and secondary antibody dilutions were applied to all sections, except for one 





Photomicrographs were acquired using an Olympus BX51 microscope (Center 
Valley, PA) fitted with a QiClick image sensor (QImaging, Surrey, BC), and CellSens 
Dimension software (version 1.13, Olympus Corporation).   
Stitched overview photomicrographs of the large sections were created by 
capturing multiple exposures at a 10x objective using an automated stage and stitched 
together by CellSens software.  Slides prepared for fluorescence were imaged as follows. 
DAPI was imaged with light filtered to 405 nm and exposure times ranging from 30-300 
ms. Lineage cells derived from Pax7 cells, signified by dTomato fluorescence, were 
imaged with light filtered to 481 nm with exposure times varying from 30-300 ms. Anti-
ColX, was imaged with the green fluorescent protein (GFP) filter with a wavelength of 
475 nm with an exposure time of 100 ms. Slides prepared for brightfield microscopy 
were imaged with an RGB filter using automatic exposure times. 
 
RNA extraction 
mRNA was extracted from the muscle and implant samples by chemical 
extraction.  Tissue samples were placed in 2 mL Eppendorf tubes with 750 µL of 
QIAzol® Lysis Reagent (Qaigen® 79306).  These were then frozen for 3-5 seconds in 
liquid nitrogen.  A 5 mm stainless steel bead (Qiagen®) was added to each tube. Samples 
were placed in chilled cassettes (Qiagen®) and lysed using the Qiagen® Tissue Lyser II 
in 2-minute intervals at 30Hz.  Degradation of the sample was monitored and care was 
taken to refreeze thawed samples if not completely lysed.  After lysing, samples were 
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moved to a separate 2 mL tube with the addition 1 mL of QIAzol® Reagent (Qiagen 
79306) and samples placed on ice for 2 minutes.   
Samples were then treated with 200 µL of chloroform (Sigma-Aldrich®) and 
vortexed to homogenize the solution. Tubes were set on ice for 2 more minutes and 
vortexed again. These were then centrifuged for 15 minutes at 14000rmp and 4°C. The 
aqueous phase of each tube was transferred to a fresh 2 mL tube. An equivalent volume 
of isopropanol (Sigma-Aldrich®) was then added to each tube, which was then inverted 
multiple times to ensure mixing. These tubes were then centrifuged for 30 min at 4°C and 
14000 rpm.  
After removing the supernatant from these tubes, the remaining pellet was washed 
with 500µL of 70% ethanol (Sigma-Aldrich®). This new solution was centrifuged for 5 
minutes at 4°C and 14000rpm. This process was repeated for an additional wash of the 
pellet. After the second ethanol wash and centrifuge, the liquid was removed and the 
tubes were left to dry, inverted on a Kimwipe for 30-60 minutes. After air-drying, pellets 
were re-suspended with RNAse free water. The volume of RNAse free water depended 
on the sample, where implants pellets received 30 µL while muscle samples received 50 
µL. Solvation of the pellet was ensured by slowly pipetting up and down. mRNA samples 
were then stored at -80°C. 
Spectroscopy and Gel Electrophoresis 
In order to ensure the quality and quantity of the extracted RNA, both gel 
electrophoresis and spectroscopy were used. 2% agarose gels with GelStarTM Nucleic 
	
21 
Acid Gel Stain from Lonza® were used to determine the presence of RNA in each 
sample. Loading samples were produced by combining 7µL of dH2O, and 2µL of 6X 
Agarose Gel Loading Dye, and 1µL of RNA sample. The gel was run at 100V for 60 
minutes. Gels were then placed under ulraviolet light, to ensure the presence of intact 
nucleic acid. 
Spectroscopy was used to quantify the concertation of RNA present in each 
sample. These measurements were obtained using an NanoDrop-1000 
Spectrophotometer. Measurements included sample concentrations (ng/µL) and sample 
purity ratios (260/280). Samples concentrations about 100 ng/µL were deemed to be large 
enough for cDNA production. 
 
cDNA Production  
A volume containing 1µg of RNA was obtained from each sample and added to a 
0.2 mL PCR tube. Varying volumes of RNAse free water was added to bring the total 
volume up to 10.4 µL. Next, reagents and enzymes from the Taqman Reverse 
Transcription Kit were added to an Eppendorf tube to create a master mix. This solution 
allowed for a total volume of 19.6 µL of reagents per sample. Reagents were added first 
with the corresponding volumes per sample, 6.61µL of MgCl2, 6.0µL of dNTP Mix, 
3.0µL of 10X RT Buffer, 1.5µL of Random Hexamers.  After vortexing, the enzymes 
RNAse Inhibitor and Taqman Reverse Transcriptase were added to solution, at 0.6µL and 
1.89µL/sample, respectively. Mixing was ensured by pulsing with pipettes or gently 
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flicking tubes. From the master mix, 19.6 µL was added to each PCR tube, bringing the 
total volume up to 30 µL.  
Real Time PCR was completed by the Eppendorf Mastercycler® Personal thermal 
cycler. After loading samples, the machine proceeded in the following steps: 25°C for 10 
minutes, 37°C for 60 minutes, 95°C for 5 minutes, finished by a 4°C hold. Following the 
PCR cycle, 20 µL RNAse free water was added to each tube to make a 1:50 dilution of 
the cDNA. Samples were then stored in -80 °C. 
 
qRT-PCR  
Quantitative Real Time PCR was completed for both implant and muscle samples. 
A 96-well qPCR plate was loaded with doublets of each sample. A solution of TaqMan® 
Universal PCR Master Mix (10 µL/sample) from and TaqMan® Gene Expression Assays 
primer (1 µL/sample) which allowed for 11 µL of this solution per sample. A list of 
primers utilized in these experiments can be found in Table 1. After aliquoting 11 µL of 
this solution to each well, 9 µL of cDNA was added. The plate was covered with 
microAMPTM optical adhesion film and centrifuged at 1500 rpm for 2 minutes.  The plate 
was analyzed using the 7300 Sequence Detector®. 
 The qRT-PCR reaction proceeded as follows: 50°C for 2 minutes, 95°C for 10 
minutes, 95°C for 15 seconds, and 60°C for 1 minute. This cycle was repeated 40 times.  
Threshold cycle values (Ct) were give a measure of the concentration of the target gene. 
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The Ct value for the target gene was normalized to 18s.  
Statistical Analysis  
Data was then visualized through graphs made with Microsoft® Office Excel 
2017.  Statistical tests were completed using JMP® 15.0.0.  Analyses included multiple 













Table 1: qRT-PCR Primers. Primers and their corresponding catalog numbers. 
Primer Catalog Number 
Normalization Primer 
18s Mm03928990_g1 









Sp7 (Osterix) Mm04933803_m1 















Prior to tissue harvesting, radiographs were obtained at the three different time 
points post implantation surgery and muscle contusion. These images were obtained for 
both periosteal and intramuscular implants to confirm the presence of ectopic bone 
formation. It was determined that mineralized bone tissue is most clearly seen on these 
radiographs for samples harvested 16 days post-surgery.   
Figure 3. Ectopic Bone Formation Most Predominate in POD 16.  Radiographs of 
both right and left hind legs harvested either 2, 8 or 16 days after surgery and injury. 



























Visualization of chondrocytes within demineralized bone matrix implants 
 Staining and immunofluorescence were completed for samples harvested 16 days 
post-surgery to identify chondrocytes to determine if the Pax7 lineage contributes to 
cartilage formation following injury. Samples were selected for the ectopic bone 
formation. Sections were first stained with Fast green/ Safranin-O to obtain an overview 
of the section and visualize the implant location, either periosteal or intramuscular. 
Ectopic bone formation was noted in POD 16 samples in both implantation locations, 
although the response seemed greater in periosteal implant samples (Figure 4; Figure 5).   
Sections from the same animal were then co-reacted with COL10A1 antibody to 
identify hypertrophic chondrocytes. The presence of dTomato positive cells was used to 
identify Pax7 expressing cells and their progeny within and around the implant.  These 
sections were treated with a collagen X antibody to label chondrocytes. Collagen X 
positive cells were found within DBM implants in both locations. These cells were found 
to a greater extent in the periosteal implant compared to intramuscular implant. Pax7 



















B.       C. 
   
 
Figure 4. Collagen X Response in Periosteal DBM Implant.  Photomicrographs were 
obtained of stained sections from an animal treated with a periosteal DBM implant and 
injury, whose tissues were harvested at POD 16. Panel A displays an overview of the 
femur, forming ectopic bone and surrounding muscle stained with Fast Green/ Safranin-
O. A portion of the ectopic bone is highlighted by the yellow square. Panel B shows a 
more focused image of the area of interest. The scale bar represents 1mm in these images. 
Panel C was treated for immunofluorescence imaging. DAPI fluoresces blue representing 
cell nuclei, the Collagen X antibody marked by green indicates chondrocytes, dTomato 






B.               C.  
   
 
Figure 5. Collagen X Response in Intramuscular DBM Implant.  Photomicrographs 
were obtained of stained sections from an animal treated with an intramuscular DBM 
implant and injury, whose tissues were harvested at POD 16. Panel A displays an 
overview of the femur, forming ectopic bone and surrounding muscle stained with Fast 
Green/ Safranin-O. A portion of the ectopic bone is highlighted by the yellow square. 
Panel B shows a more focused image of the area of interest. The scale bar represents 
1mm in these images. Panel C was treated for immunofluorescence imaging. DAPI 
fluoresces blue representing cell nuclei, the Collagen X antibody marked by green 
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indicates chondrocytes, dTomato signified with red representing Pax7 presence. Scale bar 
represents 100 µm. 
 
 
Quantitative -RT-qPCR results 
 In an attempt to determine the molecular mechanisms of ectopic bone formation 
following muscle injury, we explored the gene expression representing different cell 
populations within the implant and the tissue surrounding it.  The expression of specific 
genes involved in the endochondral ossification process were quantified.  Analyses were 
separated based on the location of the implant, either periosteal or intramuscular.  
Expression was also measured for a select set of myogenic genes in the muscle 
surrounding the implant. Tissues were harvested at 2, 8 or 16 days following DBM 
implantation and injury.  After completion of RT-qPCR, results from implant and muscle 
samples were normalized to the 18s-housekeeping gene.  Statistical analysis was 
conducted to compare differences in expression between sex, time, and implant location.  
For analyses of implant samples, Day 2 periosteal samples were excluded, due to small 
sample size, n<3.  Analysis based on sex did not show significant differences therefore 
male and female samples were pooled together.   
 
Stem Cell Involvement 
 Stem cells markers, Prx1 and Pax7, are observed early in the development of the 
musculoskeletal system.  Prx1 is implicated as a primary marker in the early stages of 
endochondral ossification, preceding the development of cartilage and bone.  Pax7 has 
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been established as a marker for satellite cells responsible for muscle growth and 
regeneration (Seale et al., 2000). 
Pax7 and Prx1 expression were observed in both periosteal and intramuscular 
implants, yet no significant differences existed between sex, location, or timing post-
surgery.  Gene expression was also measured in the muscle surrounding the implant for 
both locations.  Pax7 expression was significantly greater at Day 16 in the muscle 
associated with the periosteal implant when to compared to samples from all other time 
points for both locations (p < 0.02).  Prx1 expression was seen in the muscle surrounding 
both periosteal and intramuscular implants, yet no significant differences were observed 














Figure 6. qRT-PCR Results of Stem Cell Genes following DBM Implantation and 
Muscle Injury at Varying Time Points in Two Locations. Results were normalized to 
expression of 18s. ANOVA and Tukey testing using JMP Pro were used to determine 
significance. This was determined if the p <0.05 and is signified on graphs with **.  The 
only noteworthy relationship was for Pax7 expression in the muscle surrounding the 
implant.  Muscle tissues harvested 16 days post-surgery from around the periosteal 







































































































A number of genes related to cartilage formation help identify the early stages of 
endochondral ossification.  Quantitative RT-PCR analysis was conducted on three genes 
implicated in chondrocyte formation.  The first of these, a member of the SRY gene 
family, is Sox9 which codes a transcription factor, and is essential in initiating 
chondrogenesis.  Sox9 is highly expressed in proliferating chondrocytes, but is 
downregulated in pre-hypertrophic and hypertrophic cells, suggesting that the 
downregulation of Sox9 expression helps mark the transition from cartilage to bone.  
Another major component of the cartilage forming process is Aggrecan.  This is the 
major proteoglycan involved in the formation of articular cartilage.  Sox9 is known to 
upregulate the promoter sequence of ACAN.  The macromolecule is instrumental in 
forming the matrix of the cartilage template seen in the early stages of endochondral 
ossification. Finally, Type X collagen (Col10A) is essential for the progression of 
cartilage to bone during endochondral ossification.  Chondrocytes in the proliferating 
zone will express Type II collagen which is an important component of the extracellular 
matrix that gives the articular cartilage template some structure.  Once chondrocytes start 
undergoing hypertrophy, they will shift from synthesizing Type II collagen to Type X.  It 
is suggested that this shift helps mark the initiation and progression into the calcification 
stage of endochondral ossification.  The gene responsible for Collagen X production is 
part of the Col10A1 gene family. 
Statistical analyses concluded that no significant differences existed for samples 
grouped by time post-surgery, sex, or implant location for Sox9 and Aggrecan 
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expression. When analyzing the expression of Collagen X, day 2 groups from both 
implant locations were excluded from statistics due to small sample size (n<3).  Collagen 
X expression in the Day 8 periosteal implant was significantly greater than expression in 














































































Figure 7: q-PCR Results for Chondrogenic Markers at Varying Days Post-Surgery 
Within Periosteal and Intramuscular DBM Implants. Results were normalized to 
expression of 18s. ANOVA and Tukey testing using JMP Pro were used to determine 
significance. This was determined if the p <0.05. No significance was found for either 
Sox9 or Aggrecan. Statistically distinct samples were grouped with either *** or ** for 
Col10A samples.  
	
	
Osteogenic cell populations 
Analysis was also conducted for certain genes related to osteoblastic 
differentiation and bone mineralization processes in both implant locations.  The first of 
these is the Runx2 gene, which is part of a family of transcription factors essential in 
osteoblastic differentiation.  Additionally, the expression of Osterix, or Sp7, was 
explored.  Sp7 has been established as a transcriptional factor essential for activation of 
osteoblastic differentiation.  BGLAP, ie osteocalcin, is another osteogenic marker 
responsible for bone formation.  The gene encodes a polypeptide responsible for the 







































dentin matrix acidic phosphoprotein (DMP1) expression was also determined.  This is 
expressed in calcified tissues and is essential in controlling osteocyte differentiation.   
For Sp7 and DMP1, expression was significantly greater in day 16 periosteal 
implant samples when compared to other groups (p = 0.0181; p = 0.0417 respectively). 
















Figure 8: Genotypic Analysis of Osteogenic Genes within Periosteal and 
Intramuscular DBM Implants from Varying Days Post-Surgery. Results were 
normalized to expression of 18s. ANOVA and Tukey testing using JMP Pro were used to 
































































































Bone Morphogenetic Protein Gene Markers 
Bone morphogenetic proteins are a sub-group of the transformation growth factor 
(TGF) protein family.  Two of these proteins have been implicated in osteoblastic 
differentiation, BMP-2 and BMP-7.  BMP associated genes are not only responsible for 
aiding in osteogenesis, but also activate inhibitors of myogenesis. An example of such an 
inhibitor is ID-1 or DNA binding protein inhibitory 1. Another myogenesis inhibitor is 
myostatin (MSTN).  While this myokine is more commonly associated with skeletal 
muscle, it is also part of the TGF family, so it was included with these other markers. The 
expression of all four of these genes were measured in both implant and muscle samples.  
No significant relationships were found for the expression of these genes.  
The expression of these members of the BMP signaling cascade was also 
measured in the muscle surrounding the periosteal and intramuscular implants.  BMP-2 
expression in the muscle surrounding the periosteal was significantly higher in samples 
collected 16 days post-surgery when compared to other groups (p= 0.0166).  
Additionally, ID-1 expression in the day 2 periosteal associated muscle was significantly 
greater expression than all other groups (p =0.0003).  Lastly, day 2 periosteal associated 
muscle samples had greater expression of MSTN when compared to all other groups, 
excluding day 16 periosteal associated muscle (p=0.0307). No significant relationships 








Figure 9: qRT-PCR analysis for BMP gene markers within Periosteal and 
Intramuscular DBM Implants from Varying Days Post-Surgery.  Results were 
normalized to expression of 18s. ANOVA and Tukey testing using JMP Pro were used to 




































































































Figure 10: qRT-PCR Analysis for BMP Gene Markers within Muscle Samples 
Associated with Periosteal and Intramuscular DBM Implants from Varying Days 
Post-Surgery. Results were normalized to expression of 18s. ANOVA and Tukey testing 
using JMP Pro were used to determine significance. This was determined if the p <0.05. 
A group significantly distinct from all others are denoted by *** (BMP-2, Id-1).  For 
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Commitment to fat lineages 
 Gene markers related to fat formation were observed in both the periosteal and 
intramuscular DBM implants. One genetic marker is peroxisome proliferative activator 
receptor gamma (PPAR-g).  This protein is essential for the commitment to adipocyte 
lineage during mesenchymal stem cell differentiation. Additionally, Perilipin is a marker 
that lines lipid droplets of adipocytes.  It is a regulator of fat metabolism, and is used as a 
common indicator for the presence of adipocytes.  No significant relationships were 




Figure 11: qRT-PCR analysis for Fat-Associated Gene Markers within Periosteal 
and Intramuscular DBM Implants from Varying Days Post-Surgery.  Results were 
normalized to expression of 18s. ANOVA and Tukey testing using JMP Pro were used to 
determine significance. This was determined if the p <0.05. No significance was found 















































The expression of several genes related to myogenesis were used to explore the 
potential effect of a neighboring DBM implant on muscle cell populations.  Myogenic 
factor 5 (Myf5) and myoblast determination protein 1 are two necessary factors required 
for the development of muscle.  The expression of these genes, or lack thereof, has been 
implicated in the progression of endochondral ossification.  The gene activity of 
Myostatin was measured in the muscle surrounding the implants.  These genes were 
selected to monitor the development of ectopic bone in the tissue surrounding the DBM.  
The expression of Myf5 was the greatest in the muscle surrounding the periosteal 
implants at 8 and 16 days post-surgery (p = 0.0182) with significant increases between 
post-surgery day 2 and day 16.   The expression of MyoD in the surrounding muscle of 
the periosteal implant was significantly increased at post-surgery day 2 compared to all 






Figure 12: qRT-PCR Analysis for BMP Gene Markers within Muscle Samples 
Associated with Periosteal and Intramuscular DBM Implants from Varying Days 
Post-Surgery. Results were normalized to expression of 18s. ANOVA and Tukey testing 
using JMP Pro were used to determine significance. This was determined if the p <0.05. 
A group significantly distinct from all others are denoted by *** (MyoD).  For Myf5 
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Variation in stem cell expression 
The recruitment of Pax7 cells to the site of muscle injury has previously been 
established (Dumont et al. 2015).  While, no significant results in Pax7 expression were 
detected within implants at each location, muscle samples associated with the periosteal 
implant from POD 16 yielded higher expression rates compared to other muscle samples, 
regardless of time post-surgery or implant location.  It interesting to see a significantly 
larger expression rate in the later time point, suggesting some sort of delay or a late spike 
in stem cell expression. Additionally, although no differences were seen between Prx1 
expression rates in either implant or muscle samples, it can be noted that average Prx1 
expression was greater in implant samples when compared to their muscle counterparts 
(excluding periosteal implant POD day 2 samples). 
 
Cartilage expression peaks at POD 8 
 Collagen X expression was greater in periosteal implant samples from POD 8 
when compared to samples from the same location harvested 16 days post-surgery.  This 
is supported by previous research, which determined that chondrogenic gene markers 
peak at POD 8 following periosteal DBM implantation (B. Bragdon et al. 2017).  
Although no other significant results were found, this general trend of a POD 8 peak can 
be seen in other chondrogenic genes Sox9 and Aggrecan within the periosteal implant.  
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 For intramuscular implants, the peak in chondrogenic activity seems to be pushed 
to a later time point, peaking at POD 16.  The only group with collagen X expression 
statistically comparable to that of the POD 8 periosteal implant was the intramuscular 
implant from POD 16.  This delay in expression can be attributed to the environment 
closer to the bone being more conducive to bone forming processes due to the presence 
of cytokines and other bone promoting proteins.  The intramuscular DBM implants 
therefore take longer to initiate bone promoting signaling pathways and endochondral 
ossification.  
 
Osteogenic markers peaks at POD 16 
 Similar to chondrogenic activity, genes involved in bone formation also exhibit a 
distinct pattern of expression, peaking at POD 16 (Bragdon et al., 2017).  With 
expression peaking 16 days post- surgery, both Sp7 (Osterix) and DMP1 support this. 
RUNx2, BMP-2, BMP-7, and ID-1 all also mirror this trend in expression in the 
periosteal implant, only not to a significant extent.  
Low expression levels of RUNx2, Sp7, and DMP1 are seen within intramuscular 
implants, regardless of time post-surgery. This could be due to the delay in bone forming 
signaling suggested in the chondrogenic genes above. Because cartilage formation 
precedes bone formation in endochondral ossification, it is intuitive to assume that a 
delay in cartilage matrix formation will subsequently delay bone modeling.  Additionally, 
previous research has illuminated that intramuscular DBM implants induce less ectopic 
bone volume compared to the periosteal counterparts (Moore, 2019). This is supported by 
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comparing ectopic bone response in histological sections from Figure 4A and Figure 5A 
above.  This lower overall density could contribute to lower expression of both 
chondrogenic and osteogenic genes in the intramuscular implant.   
It can also be noted that BMP-2, BMP-7, and Id-1 expressions are comparable in 
the periosteal and intramuscular implants throughout each time point.  An explanation for 
this is that the DBM implant is supplemented with BMP-2, which could aid in the 
initiating the BMP signaling cascade before other components of the bone forming 
process are present in or around the implant.  Myostatin expression for both periosteal 
and intramuscular implants remained seemingly constant for each of the three time 
points.   
 
Differentiation into adipocytes in intramuscular implant 
 Although no significant relationship exists for the expression of PPAR-g or 
Perilipin, it is apparent that the expression of these genes is greater in the intramuscular 
implant when compared to the periosteal at each time point.  The explanation for this 
could be linked to that given above for the delay in the bone forming process in the 
intramuscular implant.  Due to the lack of bone forming cytokines present near the 
intramuscular implant, stem and progenitor cells are more likely to fall into the myocyte 





 BMP-2 activity in the muscle surrounding the periosteal implant follows the 
common trend for bone forming genetic markers, peaking at POD 16.  Interestingly, Id-1 
is significantly greater than other groups at POD 2.  The gene encodes for inhibition of 
myocyte formation, suggesting a shift in cell commitment from muscle to bone quickly 
following surgery and injury.  
 When comparing Myf5 and MyoD activity in the tissue surrounding 
intramuscular implants, no differences were found between time points.  In the muscle 
surrounding the periosteal implant, Myf5 expression mirrored the trend in expression 
shown by Pax7.  Both genes have a gradual increase in expression over time points, with 
peaks at POD 16. This connection relies on the fact that many of the cells expressing 
Myf5 will also express Pax7 (Rudnicki et al., 2008).  Myf5 expression increases 
proliferation but reduces differentiation, allowing for the accumulation of a progenitor 
pool in a flexible niche. These cells can either return to a quiescent progenitor state or 
progress to the myocyte lineage (Tedesco et al., 2010). On the other hand, MyoD 
expression upregulates the differentiation towards myocytes. The expression of MyoD is 
significantly greater at POD 2 compared to the later time points in the muscle 
surrounding the periosteal implant.  This is most likely an immediate compensatory 
reaction to the injury, attempting.  However, due to the presence to the bone promoting 
cytokines present near the periosteum, in addition to the implanted DBM and BMP-2, 




Conclusion and Future Directions 
Muscle injury produces a varied genetic response within periosteal and 
intramuscular implants, as well as in the muscle which surrounds them. Many of the 
results recapitulate previous findings. First, there is greater ectopic bone formation with 
periosteal implants when compared to the intramuscular counterpart. Secondly, for 
periosteal implants, chondrogenic activity peaks at POD 8, while osteogenic activity is 
greatest at POD 16.  Interestingly, this pattern seems to be delayed in intramuscular 
implants. Future studies could further categorize the progression of ectopic bone 
formation caused by intramuscular DBM implants, by extending genetic analysis to POD 
32.  
This study was limited by its low cohort sizes, so to better understand the 
interactions of these genes more studies must be conducted to obtain a more robust 
sample size. While only some significant relationships could be noted here, gathering 
more genetic data will better illuminate the interplay between satellite cells, muscle 
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